financetom
Business
financetom
/
Business
/
India can reach top 50 on ease of doing business index by next year: NITI Aayog CEO Amitabh Kant
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India can reach top 50 on ease of doing business index by next year: NITI Aayog CEO Amitabh Kant
Oct 31, 2018 12:57 PM

After India climbed in the World Bank's ease of doing business global rankings, Amitabh Kant, chief executive officer, NITI Aayog, on Wednesday said country can reach top 50 on index by next year.

India improved its ranking on the World Bank's 'ease of doing business' report for the second straight year, jumping 23 places to the 77th position on the back of reforms related to insolvency, taxation and other areas.

Last year, India was ranked 100th in the World Bank's Doing Business report. In its annual 'Doing Business' 2019 report, World Bank said India improved its rank on six out of the 10 parameters relating to starting and doing business in a country.

Kant said it's a remarkable achievement and the credit goes to the entire team of Department of Industrial Policy and Promotion (DIPP).

"To my mind. this is a big jump forward. We have done extremely well in getting credit, electricity and protecting minority interest. We have jumped up in construction permit also. But, we need to make up on enforcement of contracts, registering property and on starting business, where we have moved a little bit but need a big jump," Kant said to CNBC-TV18.

"This improvement in ranking shows the determination of the government that brought in major transformation through use of digital technology and doing away with human intervention in many places, improving processes and procedures, bringing in new laws and has also demonstrated the ability to bring in structural reforms like GST, insolvency code, RERA," he added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ternium Swings to Q4 Loss, Sales Decline; Shares Fall After-Hours
Ternium Swings to Q4 Loss, Sales Decline; Shares Fall After-Hours
Feb 18, 2025
04:49 PM EST, 02/18/2025 (MT Newswires) -- Ternium ( TX ) reported Q4 adjusted loss late Tuesday of $0.42 per American depositary share, compared with $2.11 profit a year earlier. Sales in the quarter ended Dec. 31 were $3.88 billion, down from $4.93 billion a year earlier. Analysts surveyed by FactSet expected $4.19 billion. The company said its board proposed...
Cadence Design Systems Q4 Earnings: Revenue Beat, EPS Beat, 'Very Well Positioned' To Benefit From AI, Shares Slide On Soft Guidance
Cadence Design Systems Q4 Earnings: Revenue Beat, EPS Beat, 'Very Well Positioned' To Benefit From AI, Shares Slide On Soft Guidance
Feb 18, 2025
Cadence Design Systems Inc ( CDNS ) reported fourth-quarter financial results and issued soft guidance after the bell. Here’s a rundown of the report. Q4 Revenue: $1.36 billion, versus estimates of $1.35 billion Q4 Adjusted EPS: $1.88, versus estimates of $1.82 Total revenue was up about 27% year-over-year in the fourth quarter. The company ended the quarter with a record...
Compass Q4 Net Loss Narrows, Revenue Rises; Shares Jump After Hours
Compass Q4 Net Loss Narrows, Revenue Rises; Shares Jump After Hours
Feb 18, 2025
04:50 PM EST, 02/18/2025 (MT Newswires) -- Compass (COMP) reported a Q4 net loss Tuesday of $0.08 per diluted share, narrowing from the loss of $0.17 a year earlier. Analysts polled by FactSet expected a loss of $0.08. Revenue in the three months ended Dec. 31 rose to $1.38 billion from $1.1 billion a year earlier. Analysts surveyed by FactSet...
Alnylam Pharmaceuticals Insider Sold Shares Worth $309,527, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $309,527, According to a Recent SEC Filing
Feb 18, 2025
04:51 PM EST, 02/18/2025 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on February 13, 2025, sold 1,213 shares in Alnylam Pharmaceuticals ( ALNY ) for $309,527. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 81,933 common shares of the company, with 81,526 shares held directly and 407 controlled indirectly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved